Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors


    PHARMACEUTICAL 2013 - Optimal capacity planning and resource allocation for a portfolio of clinical trials

    View: 526

    Website https://compliance2go.com | Want to Edit it Edit Freely

    Category PHARMACEUTICAL 2013

    Deadline: June 20, 2013 | Date: June 20, 2013

    Venue/Country: Online, U.S.A

    Updated: 2013-05-03 18:05:17 (GMT+9)

    Call For Papers - CFP

    Why you should attend

    To become familiar with newest development in optimal capacity planning and resource allocation for a portfolio of clinical trials

    Description of the topic

    Efficient strategic capacity planning and resource allocation is becoming a hot topic for biopharmaceutical companies and Clinical Research Organizations (CRO) due to increasing pressure to reduce cost of drug development. It is critical for many clinical organizations to find a better approach to increase effectiveness in resource capacity planning, especially for portfolio of clinical trials.

    When biopharmaceutical company plans to start new trials, optimal capacity planning solution means: (1) optimal resource utilization; (2) optimal resource allocation between ongoing and new trials; (3) optimal outsourcing strategy; (3) identification of resource bottleneck; (4) optimal scheduling of new trials; (5) optimal hiring and budget allocation strategy for a variety of employee roles, and (6) understaffing risk assessment.

    Effective strategic capacity planning for CRO means optimal trials “throughput”, and their allocation across therapeutic areas, and stages of development.

    Both types of organizations experience significant challenges related to resource reallocation due to trial cancellation or invocation of a new trial.

    ORBee Consulting developed powerful decision making methodology based on rigorous mathematical models for optimal capacity planning and resource allocation in clinical research. Our technique saves money (up to 30%) by uncovering better resource allocation solutions.

    Areas Covered In the Seminar

    What you will learn:

    How to apply optimization technology to capacity planning in biopharma

    How to derive workload demand and supply (overview) on a role level

    How to optimize capacity planning and resource allocation across portfolio of clinical trials for both biopharma companies and CROs.

    How to identify resource bottleneck using optimization tools

    How to reallocate resources due to inclusion or cancellation of clinical trials

    How to calculate understaffing risk

    Who will benefit

    Biopharmaceutical companies, CROs, consulting companies

    Portfolio managers

    Business analysts

    Business Development analysts

    Project managers

    Financial analysts

    Resource planners

    Executive management

    About Speaker

    Vladimir Shnaydman, Ph.D, ORBee Consulting, President (2004 ? current). The company’ focus is design and development of analytical tools and techniques for optimization of business solutions for life science industries. Company also provides consulting service, utilizing capabilities of developed tools and techniques.

    Vladimir has BS & MS Electrical Engineering & Computer Science, MS in Applied Mathematics & Operations Research, and Ph.D. in Engineering. He contributed to many industries such as biotechnology, computer networking, data storages, water resources planning and management, telecommunications, transportation, and others. Dr. Shnaydman published more than 50 papers. He is co-author of three books.

    Speaker : Dr Vladimir Shnaydman

    Product ID : F62324

    Schedule Date :

    Thursday, June 20, 2013

    duration : 12:30 to 01:30 PM EDT

    https://compliance2go.com/index.php?option=com_training&speakerkey=62&productKey=250


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.